Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
NCT06657209 on ClinicalTrials.gov · last registry update 2026-04-20
Recruiting now, toward 104 participants. Due to report 15 December 2027, alongside 38 other tracked readouts that quarter. Primary outcome, as filed: Insulin resistance in normal weight women with diabetes compared to those with no diabetes. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for diabetes and prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P4
- Drug
- tirzepatideZepbound, Mounjaro
- Sponsor
- Stanford University
- Sponsor type
- Other
- Enrollment
- 104
- Started
- 2025-01-13
- Primary completion
- 2027-12-15 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Insulin resistance in normal weight women with diabetes compared to those with no diabetes
Conditions studied
Diabetes Mellitus, Type 2 · Diabetes · Type 2 Diabetes · Pre Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.